# Vinflunine in Hormone Refractory Prostate Cancer (HRPC)

> **NCT00545766** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 41 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Vinflunine

## Key facts

- **NCT ID:** NCT00545766
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-01
- **Final completion:** 2009-01
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2021-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00545766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00545766, "Vinflunine in Hormone Refractory Prostate Cancer (HRPC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00545766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*